Wedbush reiterated their outperform rating on shares of Nuvation Bio (NYSE:NUVB - Free Report) in a research report sent to investors on Thursday morning,RTT News reports. They currently have a $5.00 price objective on the stock.
A number of other research firms have also recently weighed in on NUVB. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. HC Wainwright dropped their target price on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a report on Monday, March 10th. Finally, Jones Trading assumed coverage on Nuvation Bio in a research note on Wednesday, March 12th. They set a "buy" rating and a $10.00 price target on the stock.
Read Our Latest Analysis on NUVB
Nuvation Bio Stock Down 2.5 %
Shares of Nuvation Bio stock traded down $0.05 during trading on Thursday, reaching $1.78. The company's stock had a trading volume of 3,045,653 shares, compared to its average volume of 1,946,810. The business has a 50 day moving average price of $2.17 and a 200-day moving average price of $2.47. Nuvation Bio has a 12-month low of $1.70 and a 12-month high of $3.97. The company has a market capitalization of $601.16 million, a P/E ratio of -0.82 and a beta of 1.47.
Institutional Investors Weigh In On Nuvation Bio
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC purchased a new position in Nuvation Bio during the fourth quarter worth $27,000. Forum Financial Management LP acquired a new position in Nuvation Bio in the 4th quarter valued at about $29,000. Cerity Partners LLC purchased a new position in Nuvation Bio in the 4th quarter valued at about $31,000. Russell Investments Group Ltd. raised its position in shares of Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock valued at $42,000 after buying an additional 15,791 shares during the last quarter. Finally, Abacus Planning Group Inc. purchased a new position in shares of Nuvation Bio during the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 61.67% of the company's stock.
About Nuvation Bio
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Stories
Before you consider Nuvation Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.
While Nuvation Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
